Skip to main content
. 2020 Feb 11;21(4):1177. doi: 10.3390/ijms21041177

Figure 3.

Figure 3

DNA damage response (DDR) in PBMCs of healthy donors and CML patients. Representative Western blots of (p-)ATM and (p-)CHK2 in PBMC of three healthy donors (HEALTHY#3, HEALTHY#5, AND HEALTHY#6), two CP-CML patients in MMR (CP-CML MMR#2 and CP-CML MMR#4), two CP-CML patients with loss of MMR (CP-CML loss MMR#2 and CP-CML loss MMR#3), two de novo untreated CP-CML patients (CP-CML de novo#2 and CP-CML de novo#3), and two BP-CML patients (BP-CML#2 and BP-CML#3). In PBMCs of healthy donors, CP-CML patients in MMR, and CP-CML patients with loss of MMR, no or minor expression of p-ATM and variable expression of p-CHK2 were evident. Notably, in PBMCs of de novo CP-CML patients and BP-CML patients, no expression of p-ATM and predominantly no expression of p-CHK2 were observed (except for strong expression of p-CHK2 in BP-CML#2). SKM-1 acute myeloid leukemia cells served as positive control.